Jed A. Latkin
2020
In 2020, Jed A. Latkin earned a total compensation of $1.2M as Chief Executive Officer, Chief Operating Officer and Chief Financial Officer at Navidea Biopharmaceuticals, a 66% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $252,775 |
|---|---|
| Option Awards | $321,615 |
| Salary | $481,511 |
| Stock Awards | $163,450 |
| Other | $5,700 |
| Total | $1,225,051 |
Latkin received $481.5K in salary, accounting for 39% of the total pay in 2020.
Latkin also received $252.8K in non-equity incentive plan, $321.6K in option awards, $163.5K in stock awards and $5.7K in other compensation.
Rankings
In 2020, Jed A. Latkin's compensation ranked 7,746th out of 13,090 executives tracked by ExecPay. In other words, Latkin earned more than 40.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,746 out of 13,090 | 41st |
Division Manufacturing | 3,264 out of 5,617 | 42nd |
Major group Chemicals And Allied Products | 1,321 out of 2,248 | 41st |
Industry group Drugs | 1,144 out of 1,948 | 41st |
Industry In Vitro and In Vivo Diagnostic Substances | 20 out of 60 | 67th |
Source: SEC filing on August 2, 2021.
Latkin's colleagues
We found three more compensation records of executives who worked with Jed A. Latkin at Navidea Biopharmaceuticals in 2020.
News
Navidea Biopharmaceuticals CEO Jed Latkin's 2021 pay rises 10% to $1.3M
October 24, 2022
Navidea Biopharmaceuticals CEO Jed Latkin's 2020 pay jumps 66% to $1.2M
August 2, 2021
Navidea Biopharmaceuticals CEO Jed Latkin's 2019 pay rises 16% to $740K
July 31, 2020
Navidea Biopharmaceuticals CEO Michael Goldberg's 2018 pay jumps 76% to $1.5M
June 28, 2019